Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011:2011:405390.
doi: 10.5402/2011/405390. Epub 2011 Jun 13.

Virologic Outcome of Using Tenofovir/Emtricitabine to Treat Hepatitis B in HIV-Coinfected Patients

Christian A Engell  1 , Vinh Philip Pham, Robert S Holzman, Judith A Aberg
Affiliations

Virologic Outcome of Using Tenofovir/Emtricitabine to Treat Hepatitis B in HIV-Coinfected Patients

Christian A Engell et al. ISRN Gastroenterol. 2011.

Abstract

Goal. To study the effect of combination antiviral therapy with tenofovir and emtricitabine or lamivudine with and without prior monotherapy with lamivudine. Study. We reviewed charts of 31 HIV-/HBV-coinfected patients. Twelve 3TC-naïve patients initially received tenofovir plus emtricitabine. Nineteen epivir experienced patients who had previously failed epivir were given tenofovir plus emtricitabine. Results. Baseline median HBV DNA was similar in the epivir-naïve (5.8×10(7) copies/mL) and experienced group (7.3×10(7) copies/mL, P = .65). The median time to complete suppression of HBV was 466 days in the naïve group and 877 days in the experienced (P = .001). After 12 months, 6/10 (60%) naïve patients and 3/14 (21%) experienced patients had HBV DNA below the detectionlimit (P = .067). After 24 months, 5/5 (100%) naïve patients and 4/13 (31%) experienced patients had an undetectable HBV DNA level (P = .015). Conclusions. The median time to suppression of HBV DNA was significantly shorter among treatment naïve patients. There was a significantly greater proportion of naïve patients with suppressed HBV DNA at 24 months. Our results support using initial dual therapy in those with HIV/HBV coinfection.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Kaplan-Meier function of time to suppression.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Lavanchy D. Worldwide epidemiology of HBV infection, disease burden, and vaccine prevention. Journal of Clinical Virology. 2005;34(1):S1–S3. - PubMed
    1. The Global HIV/AIDS pandemic. Morbidity and Mortality Weekly Report. 2006;55(31):841–844. - PubMed
    1. Gaglio PJ, Sterling R, Daniels E, Tedaldi E. Hepatitis B virus and HIV coinfection: results of a survey on treatment practices and recommendations for therapy. Clinical Infectious Diseases. 2007;45(5):618–623. - PubMed
    1. Kim JH, Psevdos G, Suh J, Sharp VL. Co-infection of hepatitis B and hepatitis C virus in human immunodeficiency virus-infected patients in New York City, United States. World Journal of Gastroenterology. 2008;14(43):6689–6693. - PMC - PubMed
    1. Konopnicki D, Mocroft A, De Wit S, et al. Hepatitis B and HIV: prevalence, AIDS progression, response to highly active antiretroviral therapy and increased mortality in the EuroSIDA cohort. AIDS. 2005;19(6):593–601. - PubMed

LinkOut - more resources